419 related articles for article (PubMed ID: 17995973)
21. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
Gurbel PA; Bliden KP; Antonino MJ; Stephens G; Gretler DD; Jurek MM; Pakyz RE; Shuldiner AR; Conley PB; Tantry US
J Thromb Haemost; 2010 Jan; 8(1):43-53. PubMed ID: 19817997
[TBL] [Abstract][Full Text] [Related]
22. Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
Arya V; Mahajan P; Saraf A; Mohanty A; Sawhney JP; Bhargava M
Int J Lab Hematol; 2015 Dec; 37(6):809-18. PubMed ID: 26264906
[TBL] [Abstract][Full Text] [Related]
23. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
24. Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention.
Yao Y; Tang XF; Zhang JH; He C; Ma YL; Xu JJ; Song Y; Liu R; Meng XM; Song L; Chen J; Wang M; Xu B; Gao RL; Yuan JQ
Thromb Res; 2016 May; 141():28-34. PubMed ID: 26962983
[TBL] [Abstract][Full Text] [Related]
25. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
Michelson AD; Linden MD; Furman MI; Li Y; Barnard MR; Fox ML; Lau WC; McLaughlin TJ; Frelinger AL
J Thromb Haemost; 2007 Jan; 5(1):75-81. PubMed ID: 17002661
[TBL] [Abstract][Full Text] [Related]
26. Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists.
Spath B; Hansen A; Bokemeyer C; Langer F
Platelets; 2012; 23(1):60-8. PubMed ID: 21736422
[TBL] [Abstract][Full Text] [Related]
27. [Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy].
Muslimova EF; Afanasiev SA; Rebrova TY; Sergienko TN; Repin AN
Ter Arkh; 2017; 89(5):74-78. PubMed ID: 28631703
[TBL] [Abstract][Full Text] [Related]
28. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
[TBL] [Abstract][Full Text] [Related]
29. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
[TBL] [Abstract][Full Text] [Related]
30. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
[TBL] [Abstract][Full Text] [Related]
32. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial.
Eikelboom JW; Hankey GJ; Thom J; Claxton A; Yi Q; Gilmore G; Staton J; Barden A; Norman PE
J Thromb Haemost; 2005 Dec; 3(12):2649-55. PubMed ID: 16359503
[TBL] [Abstract][Full Text] [Related]
33. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.
Fontana P; Dupont A; Gandrille S; Bachelot-Loza C; Reny JL; Aiach M; Gaussem P
Circulation; 2003 Aug; 108(8):989-95. PubMed ID: 12912815
[TBL] [Abstract][Full Text] [Related]
34. The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease.
Matsagas M; Jagroop IA; Geroulakos G; Mikhailidis DP
Clin Appl Thromb Hemost; 2003 Apr; 9(2):115-20. PubMed ID: 12812379
[TBL] [Abstract][Full Text] [Related]
35. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients.
Bonello L; Bonello-Palot N; Armero S; Bonello C; Mokhtar OA; Arques S; Dignat-George F; Camoin-Jau L; Paganelli F
Thromb Res; 2010 Apr; 125(4):e167-70. PubMed ID: 19914687
[TBL] [Abstract][Full Text] [Related]
36. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
[TBL] [Abstract][Full Text] [Related]
37. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin.
Li Q; Chen BL; Ozdemir V; Ji W; Mao YM; Wang LC; Lei HP; Fan L; Zhang W; Liu J; Zhou HH
Pharmacogenomics; 2007 Jun; 8(6):577-86. PubMed ID: 17559347
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease.
Hamilos M; Saloustros I; Skalidis E; Igoumenidis N; Kambouris M; Chlouverakis G; Vougia D; Loggakis I; Vardas PE; Kochiadakis G
J Thromb Thrombolysis; 2015 Oct; 40(3):288-93. PubMed ID: 25662861
[TBL] [Abstract][Full Text] [Related]
39. Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
Höchtl T; Tentzeris I; Schrör K; Huber K
Fundam Clin Pharmacol; 2012 Feb; 26(1):2-10. PubMed ID: 21831128
[TBL] [Abstract][Full Text] [Related]
40. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S
Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
